Single agent umbralisib effective for relapsed slow-growing lymphoma

(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma& Myeloma, at the AACR Annual Meeting 2019 in Atlanta.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news